Lack of pharmacokinetic interaction of lacosamide on carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, topiramate and valproic acid in children and adolescents with epilepsy: Post-hoc analysis of a randomized, double-blind, placebo-controlled trial (P4.270)

Objective: To evaluate the plasma concentrations of concomitantly administrated antiepileptic drugs (AEDs) during adjunctive lacosamide (LCM) treatment in children and adolescents with focal seizures. Background: Epilepsy management often requires a combination of AEDs. Design/Methods: Post-hoc analysis of double-blind, placebo-controlled trial (SP0969; NCT01921205) of adjunctive LCM in patients (≥4– Results: The geometric mean concentrations at baseline and during LCM treatment were: CBZ 7.32μg/ml and 6.99μg/ml (n=43); LTG 5.39μg/ml and 5.88μg/ml (n=40); LEV 22.08μg/ml and 20.65μg/ml (n=63); 10-Hydroxycarbazepine (MDH) 19.18μg/ml and 19.20μg/ml (n=21); TPM 5.20μg/ml and 5.50μg/ml (n=33); VPA 74.62μg/ml and 76.80μg/ml (n=69). The geometric LS mean ratios between LCM Treatment and Baseline periods and their 90% CIs were within the 80–125% limits: CBZ 0.946 (0.885–1.010); LTG 1.127 (1.017–1.249); LEV 0.949 (0.865–1.041); MDH 1.001 (0.879–1.141); TPM 0.969 (0.870–1.080); VPA 1.000 (0.939–1.066). Similar results were observed in patients on PBO. Conclusions: The results of this post-hoc analysis showed that in children and adolescents (≥4– Study Supported by: UCB Pharma. Disclosure: Dr. Steinborn has nothing to disclose. Dr. Stockis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Armel Stockis was a full time employee of UCB Pharma until 30 June 2017 and is now a consultant to the same. Dr. Stockis holds stock and/or stock options in UCB Pharma. Dr. Zhang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Full time employee of UCB Pharma. Dr. Zhang holds stock and/or stock options in Stock options of UCB Pharma, and is a full time employee of UCB Pharma, which sponsored research in which Dr. Zhang was involved as an investigator. Dr. Zhang holds stock and/or stock options in Stock options of UCB Pharma, and is a full time employee of UCB Pharma. Dr. Dimova has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Full time employee of UCB Pharma. Dr. Dimova holds stock and/or stock options in Stock options of UCB Pharma, and is a full time employee of UCB Pharma, which sponsored research in which Dr. Dimova was involved as an investigator. Dr. Dimova holds stock and/or stock options in Stock options of UCB Pharma, and is a full time employee of UCB Pharma. Dr. Martin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Paul Martin is a full time employee of UCB Pharma. Dr. Martin holds stock and/or stock options in UCB Pharma, which sponsored research in which Dr. Martin was involved as an investigator. Dr. Martin holds stock and/or stock options in UCB Pharma.